A VLPs based vaccine protects against Zika virus infection and prevents cerebral and testicular damage.

ABSTRACT: Still, Zika virus (ZIKV) infection poses a substantial public health risk, especially for pregnant women and their fetuses, as it can result in congenital abnormalities and fetal mortality during pregnancy. Despite significant advances in understanding and combating ZIKV, considerable challenges remain in the fight against this flavivirus. A crucial component of this effort is the development of vaccines, none of which have yet been licensed for human use. Here, we present a comprehensive study of a novel ZIKV vaccine candidate based on virus-like particles (VLPs), designed to provide broad immunological protection against viral infection combined with safety, without the need for additional adjuvants. A self-adjuvanted VLPs-based vaccine displaying the envelope protein domain III (EDIII)

SUBMITTER: Cortes N 

PROVIDER: S-EPMC12116995 | biostudies-literature | 2025 May

REPOSITORIES: biostudies-literature